Gabapentin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Form (Tablet, Capsule, Oral Solution), By Type (Generic, Branded), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition, 2020-2030F

Market Overview

The Global Gabapentin Market, valued at USD 2.04 Billion in 2024, is projected to experience a CAGR of 5.60% to reach USD 2.83 Billion by 2030. Gabapentin, an anticonvulsant medication, is primarily utilized for managing neuropathic pain and as an adjunct therapy for partial seizures in epilepsy. The global market for gabapentin is significantly driven by the increasing prevalence of chronic neurological conditions, such as epilepsy and various forms of neuropathic pain, alongside the expanding geriatric population, which is more susceptible to these disorders. Furthermore, the growing medical emphasis on non-opioid alternatives for pain management has augmented gabapentin prescriptions. According to the U. S. Drug Enforcement Administration, in 2024, approximately USD 73.1 million in gabapentin prescriptions were dispensed in the United States, positioning it as the seventh most commonly prescribed medication nationally.

Despite robust growth drivers, a significant challenge impeding market expansion stems from increasing regulatory scrutiny regarding gabapentin's potential for misuse, abuse, and off-label prescribing. This has led to some jurisdictions implementing stricter monitoring or reclassifying gabapentin as a controlled substance, which could affect its accessibility and prescription rates.

Key Market Drivers

The rising prevalence of neuropathic pain disorders significantly drives the global gabapentin market, as the medication is a primary treatment option for these conditions. Neuropathic pain, resulting from nerve damage or disease, often presents as chronic and debilitating, necessitating effective pharmaceutical interventions. According to a February 2024 article published in PubMed Central titled 'Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification', the estimated prevalence of neuropathic pain in Europe is 7%–8%. This substantial patient pool continually fuels demand for gabapentin, particularly as healthcare systems worldwide prioritize managing chronic pain beyond opioid reliance. The widespread nature of conditions such as diabetic neuropathy, postherpetic neuralgia, and other nerve injury related pain syndromes ensures a consistent and growing market for gabapentin.

Another pivotal driver is the growth in the geriatric population and the associated increase in chronic conditions. Older adults are disproportionately affected by a multitude of health issues that can lead to chronic pain and neurological disorders, including epilepsy. According to the World Health Organization, in February 2025, 'Ageing: Global population', the number of people aged 60 and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. This demographic shift expands the patient base susceptible to conditions that gabapentin treats, directly influencing its market expansion. Furthermore, pharmaceutical companies continue to advance gabapentin's therapeutic profile; for instance, a 2023 collaboration between Novartis and research institutes demonstrated combination therapies involving gabapentin improved pain management effectiveness by 22%. This continuous development ensures gabapentin remains a relevant and effective treatment within an aging global demographic.

Download Free Sample Report

Key Market Challenges

Increasing regulatory scrutiny regarding gabapentin's potential for misuse, abuse, and off-label prescribing presents a significant challenge to the global market. This heightened oversight has prompted various jurisdictions to implement stricter monitoring protocols or reclassify gabapentin as a controlled substance, which directly affects its accessibility and prescription rates. Such reclassification introduces administrative complexities for healthcare providers and pharmacists, increasing the burden associated with prescribing and dispensing.

For example, in the United Kingdom, gabapentin was reclassified as a Class C controlled substance in April 2019. Consequently, the number of patients prescribed gabapentin in England, according to the NHS Business Services Authority, peaked at 926,071 in 2017/2018 and subsequently decreased to 799,155 in 2023/2024. This reduction in the patient base directly hampers market expansion by limiting the volume of new prescriptions and potentially influencing ongoing treatment decisions. The enhanced regulatory environment, therefore, creates a barrier to growth by increasing friction in the prescription pathway and fostering greater caution among prescribers.

Key Market Trends

Advancements in Extended-Release Formulations are a significant factor shaping the global gabapentin market, driven by the pharmaceutical industry's focus on enhancing patient compliance and therapeutic outcomes. These innovative formulations offer advantages by reducing the frequency of dosing, which is crucial for individuals managing chronic conditions such as neuropathic pain, thereby promoting consistent medication adherence and more stable symptom control. According to Almatica Pharma LLC, the package insert for Gralise, an extended-release gabapentin formulation, received an update in April 2023, demonstrating ongoing development and regulatory attention within this product category. This trend underscores a broader industry commitment to optimizing drug delivery systems to improve the patient experience and treatment efficacy.

The expansion of Telehealth and Digital Pharmacy Channels represents another pivotal trend influencing the global gabapentin market by transforming how patients access their medications. These digital platforms offer heightened convenience and significantly broaden reach, especially benefiting patients in underserved areas or those with mobility limitations who require continuous management for chronic pain. For example, Eli Lilly and Company launched LillyDirect™ in January 2024, a digital healthcare service designed to streamline patient access to independent healthcare providers and facilitate home delivery of certain medications via third-party pharmacies. This growing embrace of virtual care is evidenced by the American Hospital Association, which reported that over 12.6% of Medicare beneficiaries utilized a telehealth service in the final quarter of 2023, illustrating the substantial integration of digital health into mainstream medical care.

Segmental Insights

The Epilepsy segment holds a significant market share within the Global Gabapentin Market, demonstrating robust expansion. This substantial growth is primarily attributed to gabapentin's proven efficacy as an anticonvulsant, essential for managing seizures in individuals with epilepsy. The high global prevalence of epilepsy, affecting millions worldwide, coupled with increasing diagnosis rates, consistently drives demand for dependable treatment options. Furthermore, gabapentin is frequently utilized as an adjunct therapy for patients who do not respond adequately to monotherapy. Regulatory bodies, such as the U. S. FDA and the European Medicines Agency, have acknowledged gabapentin's effectiveness in controlling partial seizures, further reinforcing its clinical relevance and contributing to the segment's sustained development.

Regional Insights

North America dominates the global gabapentin market due to a significant prevalence of neuropathic pain and neurological disorders affecting a large patient base. The region boasts a well-developed healthcare infrastructure, extensive medical access, and comprehensive insurance coverage with favorable reimbursement policies. Elevated prescription rates stem from increasing healthcare provider awareness regarding gabapentin's efficacy and its broadening applications, notably in non-opioid pain management. This market leadership is further reinforced by a robust regulatory framework and a strong pharmaceutical industry, with the U. S. Food and Drug Administration overseeing drug approvals and quality standards.

Recent Developments

• In June 2025, Sunshine Biopharma Inc., through its wholly-owned Canadian subsidiary Nora Pharma Inc., launched a new generic prescription drug, Gabapentin, into the Canadian market. This anticonvulsant medication is a generic version of Neurontin® and became available in 100 mg, 300 mg, and 400 mg capsule strengths. It is intended for the treatment of neuropathic pain and epilepsy, as well as pain from conditions such as diabetic neuropathy and postherpetic neuralgia. This introduction further strengthened the company's presence in the Canadian generic drug sector, contributing to the global Gabapentin market, which was valued at $1.92 billion in 2024.

• In May 2025, breakthrough research suggested that the anti-seizure and pain medication, Gabapentin, may be associated with improved survival rates for patients diagnosed with glioblastoma, a severe form of brain cancer. A study published in Nature Communications by investigators from Mass General Brigham found that patients receiving Gabapentin survived, on average, four to six months longer than those who did not. Further analysis also indicated that patients treated with Gabapentin exhibited lower levels of serum thrombospondin-1, suggesting this protein could serve as a potential biomarker for treatment response in glioblastoma.

• In March 2024, Strides Pharma Science Limited announced that its subsidiary, Strides Pharma Global Pte. Limited, Singapore, received approval from the United States Food & Drug Administration (USFDA) for Gabapentin Tablets USP in 600 mg and 800 mg strengths. This approval expanded Strides Pharma's product offerings for neurological conditions in the US. The newly approved tablets were confirmed to be bioequivalent and therapeutically equivalent to the Reference Listed Drug, Neurontin Tablets. This regulatory milestone complemented the company's existing approval for Gabapentin capsules, reinforcing its portfolio in the Gabapentin market.

• In January 2024, Zydus Pharmaceuticals (USA) Inc., a subsidiary of Zydus Lifesciences Limited, initiated the launch of its generic version of Gralise (Gabapentin tablets) in the United States. These once-daily tablets were made available in 300 mg and 600 mg strengths, primarily indicated for the management of postherpetic neuralgia. This market entry followed a prior settlement agreement that permitted Zydus to begin selling generic versions of Gralise. The introduction of this generic formulation aimed to provide a more accessible treatment option within the Gabapentin market.

Key Market Players

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

Report Scope:

In this report, the Global Gabapentin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gabapentin Market, By Form:

o   Tablet

o   Capsule

o   Oral Solution

• Gabapentin Market, By Type:

o   Generic

o   Branded

• Gabapentin Market, By Distribution Channel:

o   Hospital Pharmacy

o   Retail Pharmacy

o   Online Pharmacy

• Gabapentin Market, By Application:

o   Epilepsy

o   Neuropathic Pain

o   Restless Legs Syndrome

o   Others

• Gabapentin Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gabapentin Market.

Available Customizations:

Global Gabapentin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Gabapentin Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]